LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31

Lexaria Bioscience Corp.

Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026

$2.60−0.26 (-9.09%)

Close on Oct 19, 2026

Market cap: $64.50M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, May 31, 2026

Lexaria Bioscience reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Lexaria Bioscience's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Lexaria Bioscience's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Aug 3, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LEXX.

Gross margin100.0% · median 22.5%

Operating margin-3973.2% · median -8963.4%

Net margin-3985.6% · median -15687.0%

Company	Revenue	Growth
CLNN	$197.00K	-31.1%
LEXX	$194.00K	-68.5%
ASBP	$97.66K	–
ABVC	–	–
IXHL	–	–
SCNX	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: August 31
Employees: 134
Auditor: MaloneBailey, LLP
SEC CIK: 1348362

Advertisement
300 × 250